Clinical Trial Update: Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study [Phase 1]

View source ↗

Summary

This Phase 1 trial of selumetinib in inoperable locally advanced or metastatic biliary tract cancer was terminated, with results posted in May 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: AstraZeneca | Conditions: Inoperable Locally Advanced or Metastatic Biliary Tract Cancer | Phase 1 | Status: TERMINATED | Results posted: 2016-05-13